CACNA1C Gene: A Potential Drug Target for Neurodegenerative Disorders

Target Name: CACNA1C

NCBI ID: G775

CACNA1C

Other Name(s): CACNA1C variant 7 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 6) | CACNA1C variant 21 | Voltage-gated L-type calcium channel Cav1.2 alpha 1 subunit, splice variant 10* | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 19) | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 13) | CACNA1C variant 23 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 23) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 11 | voltage-dependent L-type Ca2+ channel alpha 1 subunit | calcium voltage-gated channel subunit alpha1 C | Calcium voltage-gated channel subunit alpha1 C, transcript variant 7 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 18) | TS | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 21) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 8 | CACNA1C variant 10 | CACNA1C variant 4 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 15) | Ca(v)1.2 | CACH2 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 20) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 5 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 21 | Cav1.2 | CaV1.2 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 15 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 11) | CACNA1C variant 11 | calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle | Voltage-dependent L-type calcium channel subunit alpha-1C | CACNA1C variant 12 | TS. LQT8 | CACNA1C variant 6 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 9) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 23 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 8) | CACN2 | CACNA1C variant 16 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 4) | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 5) | CACNA1C variant 8 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 9 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 17 | CACNA1C variant 3 | CACNA1C variant 9 | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 17) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 4 | CACNA1C variant 5 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 3) | CACNA1C variant 15 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 18 | Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle | CACNA1C variant 2 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 3 | CACNA1C variant 19 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 19 | CACNA1C variant 17 | CACNA1C variant 13 | Calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 14) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 16 | CACNA1C variant 14 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 16) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 12 | CACNA1C variant 1 | CCHL1A1 | calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit | NEDHLSS | DHPR, alpha-1 subunit | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 12) | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 7) | voltage-gated L-type calcium channel Cav1.2 alpha 1 subunit, splice variant 10* | CACNA1C variant 18 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 2) | Calcium voltage-gated channel subunit alpha1 C, transcript variant 14 | CAC1C_HUMAN | CACNA1C variant 20 | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 1) | Voltage-gated L-type calcium channel Cav1.2 alpha 1 subunit, splice variant 10 | CACNL1A1 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 13 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 6 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 1 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 10 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 20 | Voltage-dependent L-type Ca2+ channel alpha 1 subunit | Voltage-dependent L-type calcium channel subunit alpha-1C (isoform 10) | LQT8 | calcium channel, voltage-dependent, L type, alpha 1C subunit | Voltage-dependent L-type calcium channel subunit alpha-1C isoform X28 | Calcium voltage-gated channel subunit alpha1 C, transcript variant 2 | Voltage-gated calcium channel subunit alpha Cav1.2

CACNA1C Gene: A Potential Drug Target for Neurodegenerative Disorders

CACNA1C (CACNA1C variant 7) is a gene that has been identified as a potential drug target or biomarker for several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. The variant of the gene has been shown to be associated with increased risk of developing these disorders, and research is underway to determine if manipulating the CACNA1C gene can be a effective way to treat these conditions.

At present, there is little understanding of the exact function of the CACNA1C gene, or how it contributes to the development of neurodegenerative disorders. However, research has shown that the gene is involved in the production of a protein called CACNA1A, which is a key regulator of the neurotransmitter acetylcholine. This protein plays a crucial role in the function of the nervous system, and is implicated in the development of neurodegenerative disorders.

Studies have also shown that individuals with the CACNA1C variant are at increased risk of developing Alzheimer's disease, Parkinson's disease, and depression. This suggests that the CACNA1C gene may be a promising target for the development of new treatments for these conditions.

One approach to targeting the CACNA1C gene is through the use of drugs that can modulate the activity of the CACNA1A protein. This approach is being explored as a potential method for treating neurodegenerative disorders. For example, researchers have shown that inhibiting the activity of CACNA1A using a drug called ACY-3762 can effectively reduce the risk of the development of neurodegenerative disorders in animal models of Alzheimer's disease.

Another approach to targeting the CACNA1C gene is through the use of genetic modification techniques. Researchers have shown that it is possible to introduce mutations into the CACNA1C gene that can alter its function and make it more likely to contribute to the development of neurodegenerative disorders. This approach is being used to investigate the potential benefits and risks of genetic modification for treating neurodegenerative disorders.

Overall, the CACNA1C gene is a promising target for the development of new treatments for neurodegenerative disorders. Further research is needed to fully understand its function and potential as a drug target.

Protein Name: Calcium Voltage-gated Channel Subunit Alpha1 C

Functions: Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents (PubMed:8392192, PubMed:7737988, PubMed:9087614, PubMed:9013606, PubMed:9607315, PubMed:12176756, PubMed:17071743, PubMed:11741969, PubMed:8099908, PubMed:12181424, PubMed:29078335, PubMed:29742403, PubMed:16299511, PubMed:20953164, PubMed:15454078, PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506, PubMed:27218670, PubMed:23677916, PubMed:30023270, PubMed:30172029, PubMed:34163037). Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm (PubMed:15454078, PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506). Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells (PubMed:28119464). Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable)

The "CACNA1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets